ResearcherSamsung Medical CenterNo recent work listed
Hyung‐Doo Park
Matched on ORCID iD 0000-0003-1798-773X; OpenAlex author ID A5029522190. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper
Papers 2
- Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Co-author DOI 10.18632/oncotarget.17463↗
- Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/pmic.201200101↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joon-Oh Park · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Jin Seok Heo · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Soo‐Youn Lee · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Young Suk Park · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Seong Ho Choi · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Kwang Hyuck Lee · 2 shared papers, 2012–2017 · strength 0.08
- Paper Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. DOI 10.18632/oncotarget.17463↗
- Paper Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. DOI 10.1002/pmic.201200101↗
- Kee‐Taek Jang · 1 shared paper, 2017 · strength 0.06
- Dong Wook Choi · 1 shared paper, 2017 · strength 0.06
- Jong Kyun Lee · 1 shared paper, 2017 · strength 0.06
- Jisook Park · 1 shared paper, 2017 · strength 0.06
- Eunjung Lee · 1 shared paper, 2017 · strength 0.06
- Seonwoo Kim · 1 shared paper, 2012 · strength 0.03
- Jong Kyun Lee · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.